Request Clinical Starter Kits for Your Patients Today! Request Now

Are you a clinician?

This is a clinician-only website.
By entering, you acknowledge that you're a clinician.

Pantethine supports cardiovascular health, study shows

Highlights

  • Randomized, double-blind, placebo-controlled study
  • Pantethine supports cardiovascular health, including cholesterol metabolism
  • Effective supplementation dosage is 600 to 900 mg/day

Summary

This randomized, double-blind, placebo-controlled study involved 32 middle-aged men and women living in North America at low- or moderate-risk of cardiovascular disease (CVD) and eligible for statin therapy based on the National Cholesterol Education Program (NCEP) guidelines.

Subjects followed a Therapeutic Lifestyle Change (TLC) diet for 4 weeks before starting the study and maintained the diet throughout a 16-week study period. The subjects were randomly assigned to take pantethine (600 mg/day from weeks 1 to 8 and 900 mg/day from weeks 9 to 16) or a placebo.

Compared to placebo, treatment significantly (P<.05) reduced total cholesterol (at 16 weeks), LDL cholesterol (at 8 and 16 weeks), and non-HDL cholesterol (at 16 weeks). A significant between-group difference in LDL cholesterol was found as early as week 8. These findings suggest that pantethine lowers CVD risk markers in people with low or moderate CVD risk.

Reference

Evans M, Rumberger JA, Azumano I, Napolitano JJ, Citrolo D, Kamiya T. Pantethine, a derivative of vitamin B5, favorably alters total, LDL and non-HDL cholesterol in low to moderate cardiovascular risk subjects eligible for statin therapy: a triple-blinded placebo and diet-controlled investigation. Vasc Health Risk Manag. 2014;10:89-100.

PMID: 24600231
"